AVTX Avalo Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1534120 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-77.1%
TTM net income YoY-11.4%
TTM EPS YoY81.6%
Revenue 3-yr CAGR-56.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-15,536.1%
Net margin-7,965.8%
FCF margin-11,123.8%
EBITDA margin-15,497.7%
Returns
ROE-50.1%
ROA-40.9%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets11.7%
Debt / equity0.00x
Current ratio19.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.40x
Accruals ratio16.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $59,000 | $0 | — | — | $192,000 |
| Cost of revenue | — | — | — | — | — | $0 | — | — |
| R&D expense | $15.05M | $23.42M | $14.05M | $13.27M | $13.62M | $14.07M | $9.12M | $8.18M |
| SG&A expense | $8.35M | $8.10M | $6.85M | $6.53M | $5.58M | $5.24M | $5.55M | $5.23M |
| Operating income | -$23.40M | -$31.52M | -$20.90M | -$19.74M | -$19.20M | -$19.32M | -$14.67M | -$13.31M |
| Pretax income | -$18.94M | -$36.34M | -$19.62M | -$13.59M | -$30.61M | -$20.75M | -$13.14M | -$35.23M |
| Income tax | $7,000 | $18,000 | $12,000 | $130,000 | $11,000 | $16,000 | $8,000 | $114,000 |
| Net income | -$18.95M | -$36.36M | -$19.63M | -$13.72M | -$30.62M | -$20.77M | -$13.15M | -$35.34M |
| EBITDA | -$23.38M | -$31.50M | -$20.88M | -$19.73M | -$19.14M | -$19.18M | -$14.53M | -$13.24M |
| EPS (basic) | -0.34 | -0.83 | -0.98 | — | -2.19 | -1.92 | -1.25 | — |
| EPS (diluted) | -0.34 | -0.83 | -0.98 | — | -2.19 | -1.92 | -1.25 | — |
| Weighted avg. shares (diluted) | 55.06M | 43.60M | 20.11M | — | 14.00M | 10.83M | 10.51M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $64.99M | $85.38M | $24.99M | $15.86M | $26.96M | $42.29M | $125.05M | $134.70M |
| Short-term investments | $327.98M | $314.89M | $57.01M | $82.48M | $84.65M | $70.97M | — | $0 |
| Current assets | $400.74M | $407.93M | $88.83M | $105.29M | $113.85M | $115.19M | $126.94M | $138.89M |
| Goodwill | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M |
| Total assets | $481.43M | $490.78M | $99.89M | $116.46M | $125.10M | $126.58M | $138.52M | $150.73M |
| Current liabilities | $24.09M | $21.13M | $11.60M | $12.94M | $7.97M | $9.26M | $5.62M | $6.96M |
| Total liabilities | $44.88M | $42.12M | $31.57M | $33.41M | $33.55M | $22.01M | $15.91M | $17.70M |
| Shareholders' equity | $436.55M | $448.66M | $68.32M | $83.05M | $91.55M | $104.57M | $122.61M | $133.03M |
| Shares outstanding | 53.92M | 52.90M | 24.64M | 18.51M | 17.83M | 10.84M | 10.83M | 10.47M |
| Cash flow statement | ||||||||
| Operating cash flow | -$11.54M | -$19.99M | -$17.69M | -$14.25M | -$16.36M | -$11.39M | -$9.46M | -$15.04M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$15.04M |
| Investing cash flow | -$11.23M | -$329.93M | $25.50M | $2.40M | -$13.26M | -$70.86M | $0 | $0 |
| Financing cash flow | $2.54M | $410.21M | $1.40M | $687,000 | $14.37M | -$469,000 | $0 | $67.71M |
| Depreciation & amortization | $18,000 | $17,000 | $17,000 | $16,000 | $59,000 | $134,000 | $135,000 | $68,000 |
| Stock-based compensation | $5.22M | $5.31M | $3.58M | $4.51M | $3.15M | $2.72M | $3.24M | $2.90M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.